175 related articles for article (PubMed ID: 22039254)
1. A shared gene expression signature in mouse models of EBV-associated and non-EBV-associated Burkitt lymphoma.
Bieging KT; Fish K; Bondada S; Longnecker R
Blood; 2011 Dec; 118(26):6849-59. PubMed ID: 22039254
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus LMP2A bypasses p53 inactivation in a MYC model of lymphomagenesis.
Bieging KT; Amick AC; Longnecker R
Proc Natl Acad Sci U S A; 2009 Oct; 106(42):17945-50. PubMed ID: 19815507
[TBL] [Abstract][Full Text] [Related]
3. Two Pathways of p27
Sora RP; Ikeda M; Longnecker R
mBio; 2019 Apr; 10(2):. PubMed ID: 30992353
[TBL] [Abstract][Full Text] [Related]
4. Latent membrane proteins from EBV differentially target cellular pathways to accelerate MYC-induced lymphomagenesis.
Ikeda M; Hayes CK; Schaller SJ; Longnecker R
Blood Adv; 2022 Jul; 6(14):4283-4296. PubMed ID: 35605249
[TBL] [Abstract][Full Text] [Related]
5. Suppression of the LMP2A target gene, EGR-1, protects Hodgkin's lymphoma cells from entry to the EBV lytic cycle.
Vockerodt M; Wei W; Nagy E; Prouzova Z; Schrader A; Kube D; Rowe M; Woodman CB; Murray PG
J Pathol; 2013 Aug; 230(4):399-409. PubMed ID: 23592216
[TBL] [Abstract][Full Text] [Related]
6. Virus-encoded microRNA contributes to the molecular profile of EBV-positive Burkitt lymphomas.
Piccaluga PP; Navari M; De Falco G; Ambrosio MR; Lazzi S; Fuligni F; Bellan C; Rossi M; Sapienza MR; Laginestra MA; Etebari M; Rogena EA; Tumwine L; Tripodo C; Gibellini D; Consiglio J; Croce CM; Pileri SA; Leoncini L
Oncotarget; 2016 Jan; 7(1):224-40. PubMed ID: 26325594
[TBL] [Abstract][Full Text] [Related]
7. Role of EBV and Ig/myc translocation in Burkitt lymphoma.
Klein G
Antibiot Chemother (1971); 1994; 46():110-6. PubMed ID: 7826031
[No Abstract] [Full Text] [Related]
8. Rapamycin reverses splenomegaly and inhibits tumor development in a transgenic model of Epstein-Barr virus-related Burkitt's lymphoma.
Cen O; Longnecker R
Mol Cancer Ther; 2011 Apr; 10(4):679-86. PubMed ID: 21282357
[TBL] [Abstract][Full Text] [Related]
9. SH2D1A expression in Burkitt lymphoma cells is restricted to EBV positive group I lines and is downregulated in parallel with immunoblastic transformation.
Nagy N; Maeda A; Bandobashi K; Kis LL; Nishikawa J; Trivedi P; Faggioni A; Klein G; Klein E
Int J Cancer; 2002 Aug; 100(4):433-40. PubMed ID: 12115526
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus in Burkitt's lymphoma: a role for latent membrane protein 2A.
Bieging KT; Swanson-Mungerson M; Amick AC; Longnecker R
Cell Cycle; 2010 Mar; 9(5):901-8. PubMed ID: 20160479
[TBL] [Abstract][Full Text] [Related]
11. B-cell differentiation in EBV-positive Burkitt lymphoma is impaired at posttranscriptional level by miRNA-altered expression.
Leucci E; Onnis A; Cocco M; De Falco G; Imperatore F; Giuseppina A; Costanzo V; Cerino G; Mannucci S; Cantisani R; Nyagol J; Mwanda W; Iriso R; Owang M; Schurfeld K; Bellan C; Lazzi S; Leoncini L
Int J Cancer; 2010 Mar; 126(6):1316-26. PubMed ID: 19530237
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma.
Fish K; Chen J; Longnecker R
Blood; 2014 Jan; 123(4):530-40. PubMed ID: 24174629
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A.
Dargart JL; Fish K; Gordon LI; Longnecker R; Cen O
Antiviral Res; 2012 Jul; 95(1):49-56. PubMed ID: 22609829
[TBL] [Abstract][Full Text] [Related]
14. EBV latent membrane protein 2A orchestrates p27
Fish K; Sora RP; Schaller SJ; Longnecker R; Ikeda M
Blood; 2017 Dec; 130(23):2516-2526. PubMed ID: 29074502
[TBL] [Abstract][Full Text] [Related]
15. EBV framed in Burkitt lymphoma.
Speck SH
Nat Med; 2002 Oct; 8(10):1086-7. PubMed ID: 12357244
[No Abstract] [Full Text] [Related]
16. Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma.
Niedobitek G; Agathanggelou A; Rowe M; Jones EL; Jones DB; Turyaguma P; Oryema J; Wright DH; Young LS
Blood; 1995 Jul; 86(2):659-65. PubMed ID: 7605996
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus LMP2A accelerates MYC-induced lymphomagenesis.
Bultema R; Longnecker R; Swanson-Mungerson M
Oncogene; 2009 Mar; 28(11):1471-6. PubMed ID: 19182823
[TBL] [Abstract][Full Text] [Related]
18. Spleen Tyrosine Kinase Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of Epstein-Barr Virus-Associated Lymphoma.
Cen O; Kannan K; Huck Sappal J; Yu J; Zhang M; Arikan M; Ucur A; Ustek D; Cen Y; Gordon L; Longnecker R
mSphere; 2018 Aug; 3(4):. PubMed ID: 30135222
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus LMP2A increases IL-10 production in mitogen-stimulated primary B-cells and B-cell lymphomas.
Incrocci R; McCormack M; Swanson-Mungerson M
J Gen Virol; 2013 May; 94(Pt 5):1127-1133. PubMed ID: 23303827
[TBL] [Abstract][Full Text] [Related]
20. MYC Controls the Epstein-Barr Virus Lytic Switch.
Guo R; Jiang C; Zhang Y; Govande A; Trudeau SJ; Chen F; Fry CJ; Puri R; Wolinsky E; Schineller M; Frost TC; Gebre M; Zhao B; Giulino-Roth L; Doench JG; Teng M; Gewurz BE
Mol Cell; 2020 May; 78(4):653-669.e8. PubMed ID: 32315601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
